More Companion Diagnostic Deals For Qiagen And Myriad

Qiagen’s agreement Tokai Pharmaceuticals targets circulating tumor cells, and Myriad Genetics has extended its partnership with BioMarin Pharmaceutical focused on Myriad's myChoice HRD companion diagnostic.

More from Archive

More from Medtech Insight